Open AccessTARGETED DRUG BRENTUXIMAB VEDOTIN FOR TREATMENT OF RELAPSED OR REFRACTORY CD30-POSITIVE HODGKIN’S LYMPHOMA
Author(s) -
В. Н. Степанова,
М. Э. Холовня-Волоскова,
Д. А. Андреев,
А. Д. Ермолаева,
М. В. Давыдовская,
K. Kokushkin
Publication year - 2017
Publication title -
zlokačestvennye opuholi
Language(s) - English
Resource type - Journals
eISSN - 2587-6813
pISSN - 2224-5057
DOI - 10.18027/2224-5057-2017-7-4-63-76
Subject(s) - brentuximab vedotin , medicine , cd30 , oncology , refractory (planetary science) , autologous stem cell transplantation , population , lymphoma , hodgkin lymphoma , chemotherapy , clinical trial , inclusion and exclusion criteria , transplantation , pathology , physics , alternative medicine , environmental health , astrobiology